Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?

Authors: Crow, AR  Song, S  Suppa, SJ  Ma, S  Reilly, MP  Andre, P  McKenzie, SE  Lazarus, AH 
Citation: Crow AR, etal., Blood. 2011 Jan 20;117(3):971-4. doi: 10.1182/blood-2010-05-280115. Epub 2010 Nov 2.
Pubmed: (View Article at PubMed) PMID:21045192
DOI: Full-text: DOI:10.1182/blood-2010-05-280115

To explore the potential for monoclonal antibodies as a treatment for immune thrombocytopenia (ITP) and to further explore their mechanisms of action, we tested 8 monoclonal CD44 antibodies in murine ITP and found 4 antibodies that could successfully ameliorate ITP; 2 of these antibodies function at a full 3-log fold lower dosage compared with IVIg. Further characterization of the 2 most successful antibodies (5035-41.1D and KM114) demonstrated that, similar to IVIg: (1) the presence of the inhibitory IgG receptor FcgammaRIIB was required for their ameliorative function, (2) complement-deficient mice responded to anti-CD44 treatment, and (3) human transgenic FcgammaRIIA-expressing mice also responded to the CD44 therapeutic modality. Dissimilar to IVIg, the Fc portion of the CD44 antibody was not required. These data demonstrate that CD44 antibodies can function therapeutically in murine ITP and that they could potentially provide a very-low-dose recombinant therapy for the amelioration of human ITP.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11344955
Created: 2016-07-11
Species: All species
Last Modified: 2016-07-11
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.